BioNTech Faces Pivotal Month as $1 Billion Buyback Meets Key Cancer Data and Boardroom Shake-Up

BioNTech launches $1B share buyback, but investors eye late-stage oncology data at ASCO and a board overhaul as the biotech transitions beyond COVID-19.

BioNTech is entering a defining stretch that will test both its financial firepower and its post-COVID identity. The German biotech has unleashed a fresh $1 billion share repurchase program, but investors are more focused on what comes next: a slate of late-stage oncology readouts and a restructuring of the boardroom that signals the beginning of the end for the founding era.

The buyback, authorized on May 7 and running through May 2027, allows the company to repurchase up to 4.2% of outstanding shares using its hefty cash reserves. With roughly $19.6 billion in the bank, the move is a clear signal that management believes the stock is undervalued. Yet the market has so far been unimpressed — shares closed at €79.45 on Friday, shedding nearly 10% over the past week and slipping back below the 50-day moving average. The stock now trades roughly 22% below its 52-week high of €101.90 and nearly 9% under its 200-day average.

The lukewarm reception comes despite broad analyst support. Of the 18 analysts covering BioNTech, 13 rate it a buy or strong buy, four recommend holding, and just one says sell. The average price target sits at $133, well above current levels. Still, some targets have been trimmed — Canaccord cut its price objective to $158 from $171, while Goldman Sachs and Wells Fargo maintained their buy ratings. One analyst kept a $128 target, pointing to growing momentum in the oncology pipeline.

That pipeline takes center stage later this month at the American Society of Clinical Oncology (ASCO) conference, where BioNTech will present Phase 2 data from the ROSETTA-Lung-02 study. The trial tests Pumitamig in combination with chemotherapy against the established standard of care, pembrolizumab, in non-small cell lung cancer. Management, working with partner Bristol Myers Squibb and regulators, selected progression-free survival as the primary endpoint, aiming for a statistically robust dataset.

The ASCO readout is just one of six late-stage data presentations planned for 2026, including Phase 3 interim analyses. The company has maintained its full-year revenue guidance of $2.3 billion to $2.6 billion.

Before the clinical data drops, however, shareholders will vote on a significant governance overhaul at the virtual annual general meeting on May 15. The board is set to expand from six to eight members, adding two specialists in oncology and clinical development. This new blood will oversee a sensitive task: the search for successors to founders Ugur Sahin and Özlem Türeci.

Also on the AGM agenda: approval of a new authorized capital of up to €129.5 million, representing 50% of current share capital, ratification of the 2025 compensation report, appointment of EY as auditor, and a profit-and-loss transfer agreement with fully owned subsidiary BioNTech Discovery GmbH.

The next concrete milestone after the AGM and ASCO comes on August 4, when BioNTech reports second-quarter results. Between now and then, the company must convince investors that its oncology pivot can deliver where its COVID-era windfall once did.